News: EMA Approves ALPROLIX Marketing $BIIB

European Medicines Agency has approved the Marketing Authorization Application  of ALPROLIX by Biogen and Sobi.

ALPROLIX, a recombinant factor IX Fc fusion protein product candidate for the treatment of hemophilia B. According to MAA, Phase 3 Trials for Efficacy, safety and pharmacokinetics tests would be done.

Biogen and Sobi are collaborators in the development and commercialization of ALPROLIX for hemophilia B.

View the full release here.